Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: A single institution experience

Clinical Genitourinary Cancer

Volumn 12, Issue 5, 2014, Pages 348-353

  Shetty, Aditya V ^a   Matrana, Marc R ^b   Atkinson, Bradley J ^c   Flaherty, Amber L ^d   Jonasch, Eric ^c   Tannir, Nizar M ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Hemodialysis; Kidney cancer; Kidney disease; mTOR inhibitors; VEGF tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RAPAMYCIN; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; OVERALL SURVIVAL; PNEUMONIA; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN CARCINOMA; SKIN TOXICITY; TREATMENT DURATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; EVEROLIMUS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SIROLIMUS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84922599735     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.01.004     Document Type: Article

References (15)

1. Buchler T, Pavlik T, Bortlicek Z, et al. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Med Oncol 2012; 29:3321-4
2. Howlander N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review 2011; 1975-2008. Available at: http://seer.cancer.gov/csr/1975-2010/results- merged/sect-kidney-pelvis.pdf. Accessed: January 18, 2013
3. United States Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013
4. Neuzillet Y, Tillou X, Mathieu R, et al. Renal cell carcinoma (RCC) in patients with end stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol 2011; 60:366-73
5. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-40
6. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; 27:1800-5
7. Izzedine H, Etienne-Grimaldi MC, Renee N, et al. Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 2009; 20:109-20
8. Grgic T, Mis L, Hammond JM. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. Ann Pharmacother 2011; 45:78-83
9. Masini C, Sabbatini R, Porta C, et al. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving hemodialysis: a retrospective Italian survey. BJU Int 2012; 110:692-8
10. Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012; 62:1013-9
11. Takagi T, Kondo T, Izuka J, et al. Prognosis and characteristics of renal cell carcinoma in hemodialysis patients: bilateral occurrence does not influence cancerspecific survival. Int J Urol 2011; 18:806-12
12. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-90
13. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013; 49:1287-96
14. Escudier BJ, Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)- PISCES study, NCT 01064310. Presented at June 2, 2012 ASCO Annual Meeting. J Clin Oncol 2012; 30 (abstract CRA4502)
15. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med 2013; 369:722-31.